The National Institute for Health and Care Excellence (NICE) has recommended the first bispecific antibody for the treatment of follicular lymphoma (FL). Tepkinly (epcoritamab), developed by biopharmaceutical company AbbVie, has been recommended to the NHS as an option to treat adult patients with FL whose cancer has returned or who have not responded to at least […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!